e-learning
resources
Virtual 2021
05.09.2021
Inhaled treatments for COPD: clinical trials and real-world studies
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Benefits of triple therapy in moderate, severe, and very severe COPD: subgroup analysis of the ETHOS trial
K. Rabe (Grosshansdorf, Germany), G. Ferguson (Farmington Hills, MI, United States of America), M. Jenkins (Cambridge, United Kingdom), M. Patel (Cambridge, United Kingdom), P. Dorinsky (Durham, NC, United States of America)
Source:
Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Session:
Inhaled treatments for COPD: clinical trials and real-world studies
Session type:
E-poster
Number:
791
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Rabe (Grosshansdorf, Germany), G. Ferguson (Farmington Hills, MI, United States of America), M. Jenkins (Cambridge, United Kingdom), M. Patel (Cambridge, United Kingdom), P. Dorinsky (Durham, NC, United States of America). Benefits of triple therapy in moderate, severe, and very severe COPD: subgroup analysis of the ETHOS trial. 791
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup analyses
Source: ERJ Open Res, 4 (2) 00119-2017; 10.1183/23120541.00119-2017
Year: 2018
Real-life study on the aPpropriaTeness of treatment in moderate COPD patients (OPTIMO)
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
STEP-UP randomized controlled trial of vapor ablation in patients with severe emphysema: 12 month results
Source: International Congress 2016 – Endoscopic lung volume reduction I
Year: 2016
Efficacy and safety of aclidinium/formoterol fixed-dose combination in patients with moderate to severe airflow obstruction, stratified by severity
Source: International Congress 2015 – New data on established treatments for COPD
Year: 2015
Effects of case management on hospitalisation and exacerbation rate in severe, complex COPD: A randomized controlled trial
Source: Annual Congress 2011 - Exacerbations and severe chronic respiratory disease: oxygen, rehabilitation, admission to hospital and palliative care
Year: 2011
Interval exercise for patients with severe COPD – randomised trial [SRCTN11611768]
Source: Annual Congress 2006 - Organisation and programmes in pulmonary rehabilitation
Year: 2006
Lung function and treatment patterns of symptomatic patients with moderate COPD in the CRYSTAL study
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Relationship between baseline rescue medication use and reductions in COPD exacerbation rates: a subgroup analysis of the ETHOS trial
Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies
Year: 2021
Dupilumab reduces severe exacerbation-related costs among asthma patients: Results from a phase 2b trial
Source: International Congress 2016 – How the increasing complexity of chronic care management challenges ethics and costs in our healthcare system
Year: 2016
Economic evaluation of the impact of exacerbation frequency in COPD patients treated with single-inhaler triple therapy in Spain: The IMPACT trial
Source: Virtual Congress 2020 – Pharmacological management of COPD
Year: 2020
LATE-BREAKING ABSTRACT: Treating the most diseased segments in patients with severe emphysema: 6 month results from the STEP-UP randomized controlled trial (RCT)
Source: International Congress 2015 – Advances in therapeutic bronchoscopy
Year: 2015
Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016
Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study
Source: International Congress 2019 – Novel findings from asthma clinical trials
Year: 2019
Safety and benefit of adjunctive systemic corticosteroid therapy in the management of severe, smear positive pulmonary tuberculosis (SSP-PTB); an interim analysis of a randomized controlled trial
Source: Annual Congress 2012 - Tuberculosis: clinical findings II
Year: 2012
Late Breaking Abstract - Can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial.
Source: International Congress 2017 – Late-breaking findings in asthma and COPD
Year: 2017
Cardiovascular (CV) safety of indacaterol/glycopyrronium (IND/GLY) compared with salmeterol/fluticasone combination (SFC) in moderate-to-very severe COPD patients with prior exacerbations: The FLAME study
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Top-10 comorbidities of symptomatic patients with moderate COPD in the clinical setting of the CRYSTAL study
Source: International Congress 2016 – Features and impact of comorbidities in COPD
Year: 2016
Targeted lung denervation in patients with moderate to severe COPD: AIRFLOW-2 crossover patient outcomes.
Source: Virtual Congress 2020 – The hot and cold of interventional pulmonology
Year: 2020
Comprehensive care programme for patients with chronic obstructive pulmonary disease (COPD) --- A randomized controlled trial (RCT)
Source: International Congress 2015 – Best abstracts in pulmonary rehabilitation and chronic care
Year: 2015
Tolerability and efficacy of budesonide/formoterol via Turbuhaler® vs standard treatment in Japanese patients with moderate to severe COPD: 52-week phase III study results
Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept